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Abstract
Aims The aim of this study was to evaluate the asso-
ciation of diabetes and diabetes treatment with risk of
postmenopausal breast cancer.
Methods Histologically confirmed incident cases of
postmenopausal breast (N = 916) cancer were recruited
from 23 Spanish public hospitals. Population-based
controls (N = 1094) were randomly selected from primary
care center lists within the catchment areas of the par-
ticipant hospitals. ORs (95 % CI) were estimated using
mixed-effects logistic regression models, using the re-
cruitment center as a random effect term. Breast tumors
were classified into hormone receptor positive (ER? or
PR?), HER2? and triple negative (TN).
Results Diabetes was not associated with the overall risk
of breast cancer (OR 1.09; 95 % CI 0.82–1.45), and it was
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only linked to the risk of developing TN tumors: Among 91
women with TN tumors, 18.7 % were diabetic, while the
corresponding figure among controls was 9.9 % (OR 2.25;
95 % CI 1.22–4.15). Regarding treatment, results showed
that insulin use was more prevalent among diabetic cases
(2.5 %) as compared to diabetic controls (0.7 %); OR 2.98;
95 % CI 1.26–7.01. They also showed that, among
diabetics, the risk of developing HR?/HER2- tumors
decreased with longer metformin use (ORper year 0.89;
95 % CI 0.81–0.99; based on 24 cases and 43 controls).
Conclusion This study reinforces the need to correctly
classify breast cancers when studying their association with
diabetes. Given the low survival rates in women diagnosed
with TN breast tumors and the potential impact of diabetes
control on breast cancer prevention, more studies are
needed to better characterize this association.
Keywords Diabetes Mellitus  Breast cancer  Triple-
negative breast neoplasms  Metformin  Insulin
Introduction
Diabetes mellitus and cancer are two leading causes of
death and disability worldwide. In Europe alone, by 2011
there were around 52.6 million people with diabetes, and
10 % of deaths in adults were attributed to this disease [1].
In this same continent, an estimated 3.4 million cancer
cases and 1.75 million cancer deaths occurred during 2012.
Breast, colorectal, prostate and lung tumors represented
more than half of the overall burden of cancer [2].
Substantial evidence supports that type 2 diabetes is a
risk factor for the development of numerous types of
cancer, including those of the pancreas, liver, stomach,
colorectum, kidney, bladder, postmenopausal breast and
endometrium [3]. Still, a number of important questions
remain unanswered. First, it is unclear whether this asso-
ciation can be attributed to the existence of common risk
factors for both diseases (i.e., age, obesity, lack of physical
activity), or to the direct effect of insulin resistance and its
compensatory hyperinsulinemia and hyperglycemia. Se-
cond, the latency period from diabetes exposure to cancer
risk is unknown. Because changes in glucose concentra-
tions, insulin sensitivity or insulin secretion can precede
diagnosis of diabetes to up to 6 years [4], the increased risk
of cancer could also predate clinical diagnosis of diabetes
[5]. Finally, anti-diabetes medication may also modulate
the risk of cancer, and further research is needed to dis-
entangle the effects of diabetes from those derived from its
treatment. This is even more difficult if we take into ac-
count that most diabetic patients are treated with more than
one glucose-lowering drug at the same time and that
treatment schemes change over the course of the disease
according to its severity [6].
There is epidemiological evidence showing that the as-
sociation between breast cancer and its risk factors vary
according to the expression of tumor receptors. However,
few previous reports have explored the possible role of dia-
betes on specific breast cancer subtypes [7]. The objective of
this report is to evaluate the association between diabetes and
diabetes treatment with incidence of postmenopausal breast
cancers, overall and by specific subtypes.
Materials and methods
MCC is a population-based multicase–control study in
Spain. Incidence cases of histologically confirmed breast
tumors were recruited from 23 Spanish public hospitals
from 2008 to 2013. Inclusion criteria required that cases
had lived for at least 6 months in the same study area and
were 20–85 years of age. Age- and region-matched
population controls were randomly selected from primary
care center lists. Response rates were 71 % for breast
cancer and 72 % for controls, with no differences in the
main socio-demographic variables among those who par-
ticipated and those who refused to participate. All par-
ticipants who agreed to participate signed an informed
consent, and the study was formally approved by the cor-
responding ethics committee of each area. The MCC-Spain
study also followed the Declaration of Helsinki and the
Spanish Personal Data Protection Act of 1999.
Both cases and controls were interviewed by trained
personnel, collecting data on socio-demographic factors,
health behaviors, gynecologic/obstetric history, preexisting
medical conditions, treatments received and family history
of cancer. Waist and hip circumferences were measured at
the time of the interview.
In the present study, we initially included all cases of
postmenopausal breast cancer (N = 1018) and their mat-
ched controls (N = 1243). We then excluded women with
lack of information on diabetes status (N = 43 women)
and, in order to reduce the probability of including type 1
diabetic individuals as exposed, women who had been di-
agnosed of diabetes before the age of 45 (N = 19 women).
To allow for a minimum latency period and to avoid that
the clinical conditions that lead to diabetes and cancer di-
agnosis could overlap, we also excluded women who had
been diagnosed of diabetes B1 year before the diagnosis of
cancer (N = 12 women;). Finally, to obtain effect
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estimators adjusted by BMI, we excluded 177 women with
missing values, leading to a final sample of 916 cases/1094
controls. In a sensitivity analysis, we included these par-
ticipants and imputed their BMI to check the consistency of
our results (data not shown).
Variables definition
Time since diagnosis was computed as the age at interview
minus the age at fist diagnosis of diabetes. To allow for a
minimum latency period, all potential confounders that
could be modified by the disease (tobacco and alcohol
consumption, energy intake, physical exercise) were cen-
sored to 1 year prior to the interview.
Self-reported diabetic drugs were classified according
to the Anatomical Therapeutic Chemical Classification
System of the World Health Organization. Because the
number of participants per subgroup was small, only two
main categories are considered for this report: A10A
(insulin and analogs) and A10B (blood glucose-lowering
drugs, excluding insulin). In accordance with this,
diabetic participants were classified into three groups if
they had ever received this treatment for at least 1 year:
(1) conservative therapy, (2) treatment with blood glu-
cose-lowering drugs and (3) treatment with insulin
(±anti-diabetic agents).
Tumor classification
Trained personnel reviewed all pathologic records and
registered information regarding histological type and re-
ceptor status in breast cancer cases. Breast tumors were
divided into groups according to the presence/absence of
the estrogen receptor (ER), progesterone receptor (PR) or
the human epidermal growth factor receptor (HER2) as
follows: (1) hormone receptor-positive tumors (ER? or
PR? with HER2-); (2) HER2? tumors (independent of
ER or PR) and (3) triple-negative (TN) tumors (ER-, PR-
and HER2-).
Statistical analyses
Descriptive statistics of participant characteristics were
calculated for both cases and controls by diabetes status
(Table 1). To evaluate the association between diabetic
status and cancer risk, we fitted multivariate logistic mixed
models, including the study region as a random effect term,
and adjusted for age, educational level, BMI, age of me-
narche, age at first birth, existence of previous biopsies and
family history of the studied cancer. To study whether
diabetes treatment could be associated with cancer inci-
dence, we followed two strategies. First, we evaluated the
risk of cancer associated with different treatment regimens
(conservative, oral medication, insulin ± oral medication)
using the non-diabetic population as the reference category.
Then, we quantified the association between duration of
use of specific anti-diabetic drugs and cancer risk in the
diabetic subgroup.
To explore whether the effects of diabetes, diabetes
treatment or diabetes duration could differ by cancer sub-
type, multinomial logistic models were fitted, considering
in each case the aforementioned subtypes of breast cancer.
Heterogeneity of effects was tested using a Wald test
comparing the coefficients obtained for the different
subtypes.
As sensitivity analyses, we first adjusted all models for
waist-to-hip circumference instead of BMI. Second, we
further adjusted the models for tobacco and alcohol con-
sumption, energy intake and physical exercise when this
information was available (N = 1732). Third, we explored
the results of including participants with missing values in
BMI (N = 177) after performing multiple imputation on
this variable. Fourth, we further adjusted models on dia-
betes treatment by diabetes duration. Finally, we evaluated
whether the effect of diabetes varied across categories of
BMI by introducing an interaction term between the in-
dependent variable and BMI (non-obese vs. obese). All
sensitivity analyses gave similar results (data not shown in
tables).
Results
Table 1 shows the main characteristics of the study par-
ticipants. Compared to their controls, cases were slightly
younger and had greater BMI values. Diabetic women were
older, had lower education levels, higher prevalence of
obesity and were more likely to be diagnosed with TN
tumors than those without diabetes.
Table 2 shows the results for the association between
diabetes status, diabetes management and breast cancer
risk, overall and by subtypes. After multivariate adjust-
ment, diabetic women showed no overall increased risk
of breast cancer when compared to non-diabetics (OR
1.09; 95 % CI 0.82–1.45). However, significant hetero-
geneity of the effect was observed by intrinsic subtypes
(pheterogeneity\ 0.01), with a positive association encoun-
tered for TN tumors (OR 2.25; 95 % CI 1.22–4.15).
Compared to non-diabetics, diabetic women under con-
servative management, as well as those under treatment
with oral hypoglycemic agents, showed no overall in-
creased risk of breast cancer, although, again, the results
suggested a heterogeneous effect by tumor subtype. Con-
servative management was associated with a nonsignificant
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Table 1 Main characteristics of the female population by diabetic and cancer status
Characteristics Cases p-val1
a Controls p-val1
a p-val2
b
No DM (N = 835) DM (N = 81) No DM (N = 995) DM (N = 99)
Age 62.0 (8.7) 68.9 (8.0) \0.01 64.1 (9.14) 71.7 (8.4) \0.01 \0.01
Study level
No studies 168 (20.1) 33 (40.7) 192 (19.3) 41 (41.4)
\High school 319 (38.2) 27 (33.3) 357 (35.9) 32 (32.3)
High school 235 (28.1) 15 (18.6) 283 (28.4) 16 (16.2)
[High school 113 (13.5) 6 (7.4) \0.01 163 (16.4) 10 (10.1) \0.01 0.32
BMI (kg/m2)
\25 316 (37.8) 14 (17.3) 462 (46.4) 19 (19.2)
25–30 338 (40.5) 29 (35.8) 339 (34.1) 38 (38.4)
[30 181 (21.7) 38 (46.9) \0.01 194 (19.5) 42 (42.4) \0.01 \0.01
Age menarche
\12 years 171 (20.5) 13 (16.1) 213 (21.4) 23 (23.2)
12–13 years 378 (45.2) 39 (48.1) 445 (44.7) 33 (33.4)
[13 years 286 (34.3) 29 (35.8) 0.69 337 (33.9) 43 (43.4) 0.09 0.17
Age first birth 27.0 (26.3) 27.0 (4.8) 0.21 26.0 (26.4) 27 (26.4) 0.97 0.75
Family history BC
No 721 (86.4) 72 (88.9) 905 (91.0) 83 (83.8)
Yes 114 (13.7) 9 (11.1) 0.52 90 (9.1) 16 (16.2) 0.02 \0.01
Previous biopsies
No 742 (88.9) 76 (93.8) 979 (98.4) 98 (99.0)
Yes 93 (11.1) 5 (6.2) 0.17 16 (1.6) 1 (1.0) 0.65 \0.01
Screening behavior (mammogram last 5 years)
No 91 (8.8) 17 (15.9)
Yes 949 (91.3) 90 (84.1) 0.02 \0.01
DM characteristics
Duration – 8.73 (7.9) – 8.6 (7.1) 0.95
Treatment
Conservative – 14 (17.3) – 21 (21.2)
Drugs – 67 (82.7) – 78 (78.8) 0.51
Tumor characteristics
Bilateral
Yes 798 (97.6) 79 (97.5) – –
No 20 (2.4) 2 (2.5) 0.99 – – –
Histologic subtype
Ductal 608 (85.0) 64 (87.7) – –
Lobular 53 (7.4) 4 (5.5) – –
Other 54 (7.6) 5 (6.9) 0.80 – – –
*Subtypes
RH?, HER2- 529 (73.1) 51 (66.2) – –
HER2? 121 (16.7) 9 (11.7) – –
Triple- 74 (10.2) 17 (22.1) 0.01 – – –
Data are number of participants (percentage) for categorical variables or means (SD) for continuous variables
DM diabetes mellitus
a p-val1: p value from Chi-square or ANOVA test for differences in the distribution of the studied variables by diabetic status;
b p-val2: p value
from Chi-square or ANOVA test for differences in the distribution of the studied variables by case/control status
* Numbers in tables differ because not all tumors could be classified according to intrinsic subtypes
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risk of HER2 tumors, while treatment with oral hypo-
glycemic agents alone showed a positive link with TN
breast cancer. Diabetes treatment with insulin was associ-
ated with an overall increased risk of breast cancer (OR
2.98; 95 % CI 1.26–7.01).
The last part of Table 2 shows the association between
duration of specific anti-diabetic treatments and breast
cancer risk considering only diabetic women. Analyses
based on metformin use alone showed a heterogeneous
effect of this drug over different tumor subtypes: While the
number of years under metformin treatment was not as-
sociated with the risk of HER2 or TN tumors, a negative
association with the risk of HR?/HER2- breast cancer
was observed (ORper year 0.89; 95 % CI 0.81–0.99). Du-
ration of treatment with sulfonylurea was associated with a
nonsignificant increased risk of breast cancer, after ad-
justment for insulin and metformin use (ORper year 1.05;
95 % CI 0.99–1.13). Although we could not evaluate the
dose–response association between years of insulin glar-
gine use and cancer risk due to a lack of power, we found
that women who were receiving insulin glargine at the time
of the interview had an increased risk of breast cancer
when compared to women who had never received this
drug (OR 4.97; 95 % CI 1.09–22.7).
Interaction analyses revealed no effect modification of
BMI on the association between diabetes or diabetes
management and breast cancer risk.
Discussion
Our findings do not support an overall association between
diabetes and breast cancer, although they suggest an in-
creased risk of TN tumors in postmenopausal diabetic
women. They also suggest that insulin use may increase the
risk of breast cancer. Finally, results among diabetic pa-
tients indicate that the risk of developing HR?/HER2-
tumors may decrease with longer metformin use, while the
risk of TN tumors may increase with a longer duration of
sulfonylurea use.
Despite a number of meta-analyses linking diabetes
and breast cancer incidence in postmenopausal women,
results from three recently published large population-
based studies have raised uncertainty. The first of these
null studies retrospectively evaluated the risk of breast
cancer in postmenopausal women using data from the
Columbia Linked Health Database [8]. The second,
based on record linkage between the Danish National
Diabetes Register and Cancer Registry, found no as-
sociation between diabetes prevalence or diabetes du-
ration and breast cancer risk [9]. The third, which
included 68,019 postmenopausal women followed over
a mean of 11.8 years, also failed to find an overall in-
creased risk of breast cancer among those with diabetes
[10]. However, results from this last study were mod-
ified when diabetes medication was taken into account,
as a reflection of the importance of considering diabetes
treatment when studying the risk of cancer associated
with this disease. Women under treatment with ‘‘drugs
other that metformin’’ showed a nonsignificant in-
creased risk of breast cancer (hazard ratio 1.16; 95 %
CI 0.93–1.45), while those receiving metformin pre-
sented lower incidence (hazard ratio 0.75; 95 % CI
0.57–0.99).
Differences in breast cancer risk factors by intrinsic
subtypes are well documented, and some authors have
suggested that TN tumors may be more strongly associated
with insulin resistance [11]. Our results, showing a strong
association between diabetes and incidence of TN tumors,
would support this hypothesis. However, the few previous
epidemiological studies that have evaluated the influence
of diabetes on different breast cancer subtypes have yielded
contradictory results. In the Carolina Breast Cancer Study,
an increased risk of basal-like breast tumors was seen in
postmenopausal women with higher waist circumference
and waist-to-hip ratio [12]. However, although these
measures of central adiposity are well-known markers of
insulin resistance and were strongly associated with a
history of diabetes, no elevated prevalence of diabetes was
found in women with TN tumors when compared to other
breast cancer subtypes [12]. Results from the Study of
Osteoporotic Fractures showed that diabetes was associated
with a borderline significant increased risk of ER? and
PR? cancers, while no effect was seen for ER- or PR-
[7]. Finally, a retrospective cohort study focusing on the
metabolic syndrome as a whole instead of diabetes as an
individual component found a higher prevalence of this
syndrome in patients with TN tumors, with blood glucose
being an independent risk factor for this specific subtype
[13]. In light of these conflicting results, additional re-
search is warranted.
The biological mechanisms behind a potential increased
risk of breast cancer in women with diabetes are unknown,
although are probably related to alterations in circulating
concentrations of insulin, insulin-like growth factors and
endogenous sex hormones. Insulin and IGF-1 receptors are
frequently expressed in breast cancer cells [14], with evi-
dence that their signaling pathways are of crucial impor-
tance in the role of breast cancer tumorigenesis [15, 16],
also in the case of TN tumors [17]. Insulin has a paracrine
effect on secretion of adipokines [18], which may con-
tribute to the increasing risk of more aggressive breast
tumors. Additionally, insulin can inhibit the production of
sex hormone-binding globulin in the liver [19], with sub-
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sequent increased levels of free estradiol and increasing
proliferation of breast epithelial cells.
Diabetes treatment and risk of breast cancer
Metformin
Metformin is the most commonly used drug in patients
with type 2 diabetes. Experimental studies have shown that
this biguanide drug is capable of inhibiting the proliferation
of breast cells [20]. Additionally, it can induce apoptosis of
TN [21] and HER2-positive cells [22], and it can repress
the process of epithelial-to-mesenchymal transition [23].
Interestingly, metformin also reduces the growth of several
tumoral xenografts in mice including those established
from breast cancer cells [24].
The evidence on the association between metformin use
and the risk of breast cancer has been mixed in epi-
demiologic studies [25–27]. Results from most meta-ana-
lyses have suggested a nonsignificant decreased risk of
breast cancer in metformin users [25, 26], while no effect
has emerged from randomized clinical trials (RCTs) [26].
To date, only one previous study, based on data from the
Women’s Health Initiative clinical trials, has evaluated the
incidence of specific subtypes of breast cancer in diabetic
women under metformin treatment [10]. Interestingly,
findings from this study were very similar as those from
our study, with a protective effect of metformin only ob-
served for ER?/PR? and not ER-/PR- tumors.
Sulfonylurea
A meta-analysis using data from 296,904 subjects in cohort
studies found an increased risk of total cancer among
participants using sulfonylureas when compared to non-
sulfonylurea users [28]. However, data from 6573 subjects
in RCTs and 12,040 subjects in case–control studies failed
to demonstrate a similar association [28]. Regarding breast
cancer, the evidence is scarce and the few existing studies
have yielded inconsistent findings [29–31]. Our results
point toward a possible detrimental effect of sulfonylureas
on the risk of TN breast cancer.
Insulin
Insulin is a well-known growth factor with particularly
strong mitogenic effects over cancer cells. According to
our results, showing an increased prevalence of insulin use
among cases than among controls, insulin treatment may
increase the risk of breast cancer. However, because longer
duration of insulin use among diabetics was not associated
with breast cancer risk, this positive association cannot be
easily explained based on the mitogenic effects of this drug
and it can also reflect the influence of a longer duration of
diabetes among insulin users.
Results from a meta-analysis of observational studies
have lately shown an overall increased risk of cancer in
patients treated with insulin, although a nonsignificant in-
creased risk of breast cancer (RR 1.86; 95 % CI 0.92–2.98)
was reported [32]. Data from RCTs do not support that
insulin increases the risk of total cancer, although inter-
pretation of the results is limited because cancer is not
among the end points of interest. Additionally, the few
RCTs on insulin therapy that have reported data on cancer
have focused on mortality [33].
Available data from in vitro experiments suggest that
insulin glargine may have greater proliferative effects than
human insulin in some breast cancer cell lines [34]. This
finding is supported by observational studies showing that
glargine use may be associated with an increased risk of
breast cancer [35], at least at high doses and with long
duration of treatments [5, 33]. A population-based cohort
with more than 27,000 users of insulin glargine and
100,757 users of NPH has shown a 30 % increased risk of
breast cancer in patients with ever use of glargine (RR 1.3;
95 % CI 1.0–1.8) [36]. Our results also suggest an in-
creased risk of breast cancer, although the number of
women that specifically reported the use of glargine was
too small to reach any firm conclusion.
Strengths and limitations
This is the first population-based study that evaluates the
association between diabetes and breast cancer in the
Spanish population. Our main strength is that we have
histologically confirmed incident cases and that we have
classified tumors according to their receptor status. Very
few studies have previously evaluated the association be-
tween diabetes and breast cancer by specific subtypes, and
our results suggest the importance of this approach.
Since our results are based on a case–control study,
several methodological limitations may exist. First, dia-
betes history is self-reported and so it is subjected to recall
bias. According to the International Diabetes Federation,
around 35 % of the European diabetic population is una-
ware of having this condition [1]. However, we expect
underdiagnosis not to be so important in our population
because participants had frequent contact with the health
system, as reflected by their high prevalence of screening
behaviors. Additionally, results from a meta-analysis on
the association between diabetes and breast cancer showed
that findings were unchanged when the diagnosis of dia-
betes was self-reported or confirmed with medical records
[37]. Second, we were limited by the sample size, par-
ticularly for evaluating certain subgroup associations.
Third, it is hard to disentangle the effects of diabetes
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treatment from those of the disease itself. As an example,
diabetic patients receiving insulin are a subgroup with very
specific characteristics; they usually have more severe
forms of diabetes and greater prevalence of comorbidities
that can lead to an increased risk of cancer. Fourth, indi-
viduals receiving insulin usually visit their doctors more
frequently, and this may increase their probability of
screening and cancer detection. Additionally, we do not
have information on glycemic control, and we can there-
fore not evaluate its potential mediating role in the ob-
served associations. Finally, although many confounders
have been taken into account, we cannot rule out some
residual confounding by lifestyle-related factors associated
with both diabetes and breast cancer development.
Conclusions
Our findings do not support an overall association between
diabetes and breast cancer, but they provide some sug-
gestive hypothesis for associations with particular tumor
subtypes. Although our results should be interpreted with
caution due to limitations in sample size, results suggest
that diabetes may increase the risk of TN breast tumors.
Given the low survival rates in women diagnosed with TN
breast tumors, more studies are needed to better charac-
terize this association.
Acknowledgments The authors would like to thank all members of
the Multi-Case Control (MCC) Spain Endocrine Study Group: Juan
Alguacil, Mikel Azpiri, Laura Costas, Marta Crous, Marian Dı´az
Santos, Marieta Ferna´ndez Cabrera, Emiliano Honrado, Virginia
Lope, Jaime Mendiola, Carmen Navarro, Nicola´s Olea, Miquel Porta,
Jose´ Pumarega, Dolores Salas Trejo, Oscar Sanz, Cristina Villanueva
Belmonte, Esteban Vizacaino. Dr. Garcı´a-Esquinas was supported by
a Rı´o Hortega (CM10/00332) research training Grant from the
Spanish Ministry of Economy and Competitiveness (Carlos III In-
stitute of Health) and by the Enrique Na´jera predoctoral Grant
awarded by the Spanish Society of Epidemiology and funded by the
National School of Public Health. This work was supported by re-
search Grants from Spain´s Health Research Fund Fondo de Investi-
gacio´n Sanitaria (PI12/00488, PI08/1770, PI08/0533, PI08/1359,
PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662,
PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/
00265, PI12/01270, PI12/00715, PI12/00150), Fundacio´n Marque´s de
Valdecilla (API 10/09), ICGC International Cancer Genome Con-
sortium CLL, Junta de Castilla y Leo´n (LE22A10-2), Consejerı´a de
Salud of the Junta de Andalucı´a (PI-0571), Conselleria de Sanitat of
the Generalitat Valenciana (AP_061/10), Recercaixa (2010ACUP
00310), Regional Government of the Basque Country by European
Commission GrantsFOOD-CT-2006-036224-HIWATE, Spanish As-
sociation Against Cancer (AECC) Scientific Foundation and the
Catalan Government DURSI Grant 2014SGR647.
Conflict of interest Authors declare no conflicts of interest.
Human and Animal Rights All procedures followed were in ac-
cordance with the ethical standards of the responsible committee on
human experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2008.
Informed consent Informed consent was obtained from all patients
for being included in the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. IDF (2013) Diabetes Atlas. 5th Edition. Brussels: International
Diabetes Federation, 2012. http://www.idf.org/diabetesatlas/5e/
europe
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coe-
bergh JW, Comber H et al (2013) Cancer incidence and mortality
patterns in Europe: estimates for 40 countries in 2012. Eur J
Cancer 49(6):1374–1403
3. Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and
cancer risk: review of the epidemiological evidence. Cancer Sci
104(1):9–14
4. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M,
Witte DR (2009) Trajectories of glycaemia, insulin sensitivity,
and insulin secretion before diagnosis of type 2 diabetes: an
analysis from the Whitehall II study. Lancet
373(9682):2215–2221
5. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L,
Renehan AG (2012) Diabetes and cancer (1): evaluating the
temporal relationship between type 2 diabetes and cancer inci-
dence. Diabetologia 55(6):1607–1618
6. Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and
cancer: a consensus on complexity. Lancet 375(9733):2201–2202
7. Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA
(2012) Components of metabolic syndrome and risk of breast
cancer by prognostic features in the study of osteoporotic frac-
tures cohort. Cancer Causes Control 23(8):1241–1251
8. Bowker SL, Richardson K, Marra CA, Johnson JA (2011) Risk of
breast cancer after onset of type 2 diabetes: evidence of detection
bias in postmenopausal women. Diabetes Care 34(12):2542–2544
9. Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in
Danish diabetic patients: duration and insulin effects.
Diabetologia 55(4):948–958
10. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE,
Aragaki AK, Rohan T et al (2012) Diabetes, metformin, and
breast cancer in postmenopausal women. J Clin Oncol
30(23):2844–2852
11. Davis AA, Kaklamani VG (2012) Metabolic syndrome and triple-
negative breast cancer: a new paradigm. Int J Breast Cancer
2012:809291
12. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K,
Dressler LG et al (2008) Epidemiology of basal-like breast can-
cer. Breast Cancer Res Treat 109(1):123–139
13. Maiti B, Kundranda MN, Spiro TP, Daw HA (2010) The asso-
ciation of metabolic syndrome with triple-negative breast cancer.
Breast Cancer Res Treat 121(2):479–483
14. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR,
Vigneri R et al (1992) Insulin receptor expression and function in
human breast cancer cell lines. Cancer Res 52(14):3924–3930
106 Acta Diabetol (2016) 53:99–107
123
15. Parisot JP, Hu XF, DeLuise M, Zalcberg JR (1999) Altered ex-
pression of the IGF-1 receptor in a tamoxifen-resistant human
breast cancer cell line. Br J Cancer 79(5–6):693–700
16. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor
signaling as a potential cancer therapy. Mol Cancer Ther
6(1):1–12
17. Davison Z, de Blacquiere GE, Westley BR, May FE (2011) In-
sulin-like growth factor-dependent proliferation and survival of
triple-negative breast cancer cells: implications for therapy.
Neoplasia 13(6):504–515
18. Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines
and insulin resistance. Mol Med 14(11–12):741–751
19. Haffner SM (1996) Sex hormone-binding protein, hyperinsu-
linemia, insulin resistance and noninsulin-dependent diabetes.
Horm Res 45(3–5):233–237
20. Dowling RJ, Goodwin PJ, Stambolic V (2011) Understanding the
benefit of metformin use in cancer treatment. BMC Med 9:33
21. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al
(2009) Metformin induces unique biological and molecular re-
sponses in triple negative breast cancer cells. Cell Cycle
8(13):2031–2040
22. Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY et al
(2013) Metformin inhibits proliferation and promotes apoptosis
of HER2 positive breast cancer cells by downregulating HSP90.
J BUON 18(1):51–56
23. Vazquez-Martin A, Oliveras-Ferraros C, Del BS, Martin-Castillo
B, Menendez JA (2011) The anti-diabetic drug metformin sup-
presses self-renewal and proliferation of trastuzumab-resistant
tumor-initiating breast cancer stem cells. Breast Cancer Res Treat
126(2):355–364
24. Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P,
Auberger P et al (2008) The antidiabetic drug metformin exerts
an antitumoral effect in vitro and in vivo through a decrease of
cyclin D1 level. Oncogene 27(25):3576–3586
25. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in
diabetic patients treated with metformin: a systematic review and
meta-analysis. PLoS ONE 7(3):e33411
26. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F,
Nicolucci A (2013) Metformin therapy and risk of cancer in
patients with type 2 diabetes: systematic review. PLoS ONE
8(8):e71583
27. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS,
van Veldhoven K et al (2014) Metformin does not affect cancer
risk: a cohort study in the UK Clinical Practice Research Datalink
analyzed like an intention-to-treat trial. Diabetes Care
37(9):2522–2532
28. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS
(2013) Metformin and sulfonylureas in relation to cancer risk in
type II diabetes patients: a meta-analysis using primary data of
published studies. Metabolism 62(7):922–934
29. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012) Oral
insulin secretagogues, insulin, and cancer risk in type 2 diabetes
mellitus. J Clin Endocrinol Metab 97(7):E1170–E1175
30. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH
(2012) The influence of type 2 diabetes and glucose-lowering
therapies on cancer risk in the Taiwanese. Exp Diabetes Res
2012:413782
31. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013)
Initial metformin or sulphonylurea exposure and cancer occur-
rence among patients with type 2 diabetes mellitus. Diabetes
Obes Metab 15(4):349–357
32. Janghorbani M, Dehghani M, Salehi-Marzijarani M (2012) Sys-
tematic review and meta-analysis of insulin therapy and risk of
cancer. Horm Cancer 3(4):137–146
33. Mannucci E (2012) Insulin therapy and cancer in type 2 diabetes.
ISRN Endocrinol 2012:240634
34. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M
(2007) Comparison of the mitogenic potency of regular human
insulin and its analogue glargine in normal and transformed hu-
man breast epithelial cells. Horm Metab Res 39(1):65–67
35. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak
HR, Geelhoed-Duijvestijn PH et al (2012) Risk of cancer in pa-
tients on insulin glargine and other insulin analogues in com-
parison with those on human insulin: results from a large
population-based follow-up study. Diabetologia 55(1):51–62
36. Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den
Eeden SK, Weiss NS et al (2013) Cohort study of insulin glargine
and risk of breast, prostate, and colorectal cancer among patients
with diabetes. Diabetes Care 36:3953–3960
37. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F,
Coppens K et al (2012) Diabetes and breast cancer risk: a meta-
analysis. Br J Cancer 107(9):1608–1617
Acta Diabetol (2016) 53:99–107 107
123
